AHFS Drug Information®

An Evidence-based Foundation for Safe and Effective Drug Therapy

AHFS Drug Information®
2024 Ed.
2024 © American Society of Health-System Pharmacists®
American Society of Health-System Pharmacists
ISBN-13: 978-1-58528-721-5
Pharmacy/Pharmacology, Drug Information, Neurology, Ophthalmology, Point of Care, Public Health


2020, 2021, 2022, 2023 Doody's Core Titles List Selection I 5-Star Rating from Doody's Review Service

AHFS DI is the most comprehensive evidence-based source of drug information complete with therapeutic guidelines and off-label uses. With expanded and revised content supported by more than 97,000 references and incorporating the advice of numerous subject matter experts, AHFS DI helps you protect your patients.

Benefits that are unique to AHFS DI include:

  • • The only remaining original federal compendium whose authority for establishing accepted medical uses includes the broadest scope of drugs and indications under Medicaid, Medicare Part D, and more.
  • • The only drug information resource with content developed by a professional editorial and analytical staff of pharmacists for a not-for-profit scientific organization.

2024 Edition Updates

  • • Clinical perspective sections that include place of therapy discussions and recommendations from therapeutic guidelines
  • • Expanded coverage of specialty medications used to treat a variety of complex, chronic conditions that often require special handling and administration and may require careful oversight to manage severe adverse effects and dosage adjustments
  • • Contemporary topics such as new RSV treatments and vaccines, safety issues associated with glucagon-like peptide 1 (GLP-1) agonists, novel orphan drugs, biosimilars, and more
  • • Inclusion of MedWatch alerts, Standardize4Safety information, REMS data, and focused FDA updates for various medications
  • • Expanded content on new and emerging gene therapies
  • • Updates to a variety of vaccine monographs including the pneumococcal, influenza, rabies, and COVID-19 mRNA vaccines
  • • Expanded content on off-label uses, real-world data, and long-term clinical data
  • • New content on over 175 new molecular entities (NMEs) or new therapeutic biological products and substantive revisions on approximately 190 medications

This title updates: Monthly

Doody's Reviews

Doody's Core Titles (DCT)
Essential Purchase Title (EPT)
Specialty Score: 2.6 Health Sciences - Pharmacy
Go to Doody's Review page

Quotes, Reviews or Testimonials

"This book is a valuable reference to access drug information, from current therapeutic guidelines to off-label uses. The updates in the 2023 reference contain the latest information about COVID-19 vaccines and therapeutics, contemporary treatment topics, Standardized 4 Safety concentration standards for IV and oral liquid drugs, breakthrough oncology drugs approved through the FDA's accelerated approval program, and pharmacogenomic considerations. The updates also contain clinical perspective sections that include place of therapy discussions and recommendations from therapeutic guidelines."

-- Yen Dang, PharmD (University of Maryland Eastern Shore) Doody's Review - previous edition

"This book succeeds in offering an updated drug compendium of evidence-based drug monographs, meeting the needs of today's healthcare professionals. The reference continues to be trustworthy, relying on the most prestigious and knowledgeable drug experts in the medical field. Current topics are incorporated, such as breakthrough oncology drugs, pharmacogenomics, off-label drug uses, and opioid use disorder. It is a worthy addition to the personal library of physicians, pharmacists, nurse practitioners, and other prescribers."

-- Melissa Potts, BS, PharmD (Temple University School of Pharmacy) Doody's Review - previous edition

"This reference is widely used and trusted for its established record in refuting unfounded efficacy claims, its rigorous science-based editorial process, and its independence from the influence of pharmaceutical manufacturers."

-- Jennifer Colon, PharmD, MS, MBA (Temple University School of Pharmacy) - previous edition

"You cannot be a pharmacist without this book. For clinical pharmacists especially it is the standard..."

-- Miriam Klein, Pharm.D. R.Ph. (Woodhull Medical Center) - previous edition


The book is written for pharmacists and other healthcare providers to access specific guidance needed to prescribe and monitor drug therapy safely and effectively. It includes over 97,000 cited references linked to 735,000 statements with 70,000 supporting evidence sources. Using an independent, evidence-based evaluative process, the drug monographs incorporate information from pertinent references in the literature and expert therapeutic guidelines. This point-by-point analysis and evaluation of the literature make this reference comprehensive, evaluative, and unbiased.

Table of Contents

Similar Resources